Breaking News Headlines Today

News about Bill Blair

Stay current with all the latest and breaking news about Bill Blair, compare headlines and perspectives between news sources on stories happening today. In total, 66 stories have been published about Bill Blair which Ground News has aggregated in the past 3 months.

Media Bias Breakdown

How is the media covering Bill Blair?

Bill Blair often is covered by Center Media sources.

12%

Center: 76%

12%

Covered Most by:

Center9 recent stories

Center6 recent stories

Unknown9 recent stories

Unknown7 recent stories

Covered Most By

William Blair’s top 2026 picks in tech, media, and communications: META, INTU and more

100% Right coverage: 1 sources

Bill Blair Read Article

Andersen Announces Launch of Initial Public Offering

Tax advisory firm Andersen Group is targeting a valuation of up to $1.75bn in its initial public offering (IPO) in the US. In September 2025, the company filed a registration statement with US Securities and Exchange Commission (SEC) to list its shares on New York Stock Exchange (NYSE) under the symbol ANDG. The IPO aims to offer 11 million shares at an estimated price range between $14 and $16 per share, with the goal of raising up to $176m.…Bill Blair See the Story

Why Shares of Simulations Plus Soared This Week

100% Left coverage: 1 sources

Key PointsShares of Simulations Plus had gained more than 20% as of midday Thursday.The company reported mixed results, but its guidance calls for revenue and earnings growth in fiscal 2026 despite a difficult environment.Simulations Plus will lay out its AI-centric product vision in January.10 stocks we like better than Simulations Plus › While modeling and simulation software provider Simulations Plus (NASDAQ: SLP) reported mixed results for t…Bill Blair · Lancaster See the Story

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza - Viridian Therapeutics (NASDAQ:VRDN)

100% Center coverage: 1 sources

William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday. Analyst Lachlan Hanbury-Brown writes that the company's anti-IGF-1R franchise represents a meaningful advance compared to Amgen Inc.’s (NASDAQ:AMGN) Tepezza (teprotumumab-trbw) for thyroid eye disease (TED). TED is a rare autoimmune disorder characterized by inflammation and swelling of the tissues around the eyes, often leading to pain, vision impairment.…Bill Blair · United States See the Story

EMD comes of age: why emerging markets debt now deserves a strategic allocation

By Marcelo Assalin, Head of Emerging Markets Debt, William Blair Investment Management Emerging markets debt is shedding its old reputation as a high-beta, niche corner of fixed income. With a $44 trillion market, strengthened policy frameworks, and increasingly credible institutions, the asset class has matured into a diversified, resilient and opportunity-rich component of global bond portfolios. As EM central banks ease ahead of developed mar…Bill Blair Read Article

APA, Coterra, Ovintiv started Outperform at William Blair, citing strong free cash flow

100% Right coverage: 1 sources

Bill Blair · Chicago Read Article

Investors Should Buy the Dip in Coinbase (COIN) and Circle (CRCL), Says William Blair

100% Center coverage: 1 sources

The latest crypto slide has created an attractive entry point for the two companies' stocks, with core USDC and bitcoin theses still intact.Bill Blair · United States See the Story

News about Bill Blair

News about Bill Blair

Media Bias Breakdown

Media Bias Breakdown

Covered Most By

William Blair’s top 2026 picks in tech, media, and communications: META, INTU and more

Andersen Announces Launch of Initial Public Offering

Why Shares of Simulations Plus Soared This Week

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza - Viridian Therapeutics (NASDAQ:VRDN)

EMD comes of age: why emerging markets debt now deserves a strategic allocation

APA, Coterra, Ovintiv started Outperform at William Blair, citing strong free cash flow

Investors Should Buy the Dip in Coinbase (COIN) and Circle (CRCL), Says William Blair

DLA Piper advises the underwriters in Exzeo Group’s US$168 million IPO

Wall Street Loves Nvidia Heading Into Earnings

FY2025 Earnings Estimate for MaxCyte Issued By William Blair

Covered Most By

Breaking News Topics Related to Bill Blair

William Blair’s top 2026 picks in tech, media, and communications: META, INTU and more

Andersen Announces Launch of Initial Public Offering

Why Shares of Simulations Plus Soared This Week

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza - Viridian Therapeutics (NASDAQ:VRDN)

EMD comes of age: why emerging markets debt now deserves a strategic allocation

APA, Coterra, Ovintiv started Outperform at William Blair, citing strong free cash flow

Investors Should Buy the Dip in Coinbase (COIN) and Circle (CRCL), Says William Blair

DLA Piper advises the underwriters in Exzeo Group’s US$168 million IPO

Wall Street Loves Nvidia Heading Into Earnings

FY2025 Earnings Estimate for MaxCyte Issued By William Blair